Recent developments in antibody derivatives against colorectal cancer; A review

Life Sci. 2021 Jan 15:265:118791. doi: 10.1016/j.lfs.2020.118791. Epub 2020 Nov 19.

Abstract

Colorectal cancer (CRC) is the fourth most common cause of cancer and mortality worldwide and is the third most common cancer in men and women. Surgery, radiotherapy, and chemotherapy are conventionally used for the treatment of colorectal cancer. However, these methods are associated with various side effects on normal cells. Thus, new studies are moving towards more effective and non-invasive methods for treatment of colorectal cancer. Targeted therapy of CRC is a promising new approach to enhance the efficiency and decrease the toxicity of the treatment. In targeted therapy of CRC, antibody fragments can directly inhibit tumor cell growth and proliferation. They also can act as an ideal carrier for targeted delivery of anticancer drugs. In the present study, the structure and function of different formats of antibody fragments, immune-targeted therapy of CRC using antibody fragments will be discussed.

Keywords: Antibody derivatives; Colorectal cancer; Colorectal cancer markers; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neoplasm / administration & dosage*
  • Antibodies, Neoplasm / immunology*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / immunology*
  • Biomarkers, Tumor / immunology
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / immunology*
  • Drug Development / trends
  • Humans
  • Immunotherapy / methods
  • Immunotherapy / trends

Substances

  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Biomarkers, Tumor